Cipher Pharmaceuticals (TSE:CPH) Shares Cross Above Fifty Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$16.67 and traded as high as C$16.84. Cipher Pharmaceuticals shares last traded at C$16.40, with a volume of 9,804 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$17.00 target price on Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of C$17.00.

Cipher Pharmaceuticals Stock Down 1.0%

The stock’s fifty day simple moving average is C$16.67 and its two-hundred day simple moving average is C$16.43. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.25 and a quick ratio of 2.67. The company has a market capitalization of C$416.41 million, a price-to-earnings ratio of 13.78 and a beta of 1.15.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The business had revenue of C$17.39 million during the quarter. On average, sell-side analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.